STOCK TITAN

Pulmatrix - PULM STOCK NEWS

Welcome to our dedicated page for Pulmatrix news (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix stock.

Overview

Pulmatrix Inc (PULM) is a clinical-stage biotechnology company dedicated to transforming the field of inhaled therapeutics. With a strong foundation in advanced drug delivery sciences, Pulmatrix is focused on the discovery and development of novel inhaled therapeutic products designed to address critical respiratory and central nervous system disorders that present significant unmet medical needs. The company has positioned itself at the intersection of pharmaceutical science and cutting-edge particle engineering, making its innovations highly relevant to both healthcare providers and investors seeking scientifically validated approaches to disease management.

Innovative iSPERSE Technology

The heart of Pulmatrix's innovation lies in its patented dry powder technology, iSPERSE, which stands for "inhaled Small Particles Easily Respirable and Emitted." This technology represents a paradigm shift in inhalation therapy by producing particles that are purposely engineered to be small, dense, and exceptionally dispersible. Such properties enable efficient delivery of drugs deep into the lungs while maximizing local concentrations and minimizing systemic side effects. The inherent versatility of the iSPERSE platform allows it to be integrated with various dry powder inhaler devices, thereby accommodating a broad spectrum of drug substances ranging from small molecule compounds to peptides, proteins, and nucleic acids.

Therapeutic Product Pipeline

Pulmatrix’s pipeline is strategically designed to target diseases where inhalation delivery can yield clinically significant benefits. Focusing on both respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and other pulmonary infections, as well as central nervous system disorders including acute migraine, the company is exploring clinical applications where improved local drug delivery results in enhanced therapeutic outcomes. By emphasizing localized treatment, Pulmatrix aims to deliver medications that work more efficiently at the site of disease action while potentially mitigating overall systemic exposure, which is a distinct advantage over traditional routes of administration.

Business Model and Market Position

Operating as a clinical-stage biopharmaceutical entity, Pulmatrix’s strategy revolves around the discovery, development, and eventual commercialization of its innovative inhaled products. The company derives its value from a combination of advancing clinical programs and leveraging strategic partnerships and licensing agreements. Its emphasis on technological innovation and solid scientific methodology positions it uniquely among its peers in the biotechnology sector. Pulmatrix differentiates itself by focusing on a specialized drug delivery platform that challenges the limitations of conventional aerosol and nebulized therapies, thereby offering a competitive alternative in high-need therapeutic areas.

Industry and Regulatory Context

In the highly regulated realm of biotechnology, compliance with stringent safety and quality standards is paramount. Pulmatrix operates under rigorous regulatory oversight, ensuring its clinical trials meet evolving guidelines for safety, efficacy, and quality control. The company’s methodical approach to clinical testing, which includes detailed assessments of pharmacokinetics, tolerability, and dose optimization, exemplifies its commitment to precision and responsibility in the development of novel therapeutics. This regulatory focus not only reinforces confidence in its scientific output but also contributes to the overall trust placed in its advanced drug delivery solutions.

Collaborations and Strategic Partnerships

Pulmatrix has established a network of strategic alliances that bolster its clinical programs and technological capabilities. Through licensing agreements and collaborative transactions with other leading companies in the industry, Pulmatrix is able to enhance the commercialization potential of its iSPERSE platform. Such partnerships facilitate access to complementary technologies and market channels, thereby strengthening the company’s position within the competitive landscape of inhaled therapeutics. These collaborative efforts provide financial flexibility and strategic insight, ensuring that Pulmatrix remains agile and capable of adapting to evolving market dynamics.

Clinical Development Focus

The company’s clinical development programs are designed with rigorous scientific scrutiny to ensure that every product candidate is backed by robust clinical data. Pulmatrix’s trials focus on assessing quickly acting treatments with optimized safety profiles—a critical consideration for acute conditions such as migraine and chronic pulmonary disorders. The emphasis on detailed pharmacodynamic and pharmacokinetic evaluations is reflective of its commitment to evidence-based medicine and comprehensive patient care. By systematically refining dosage and delivery methodologies, Pulmatrix lays a strong foundation for future clinical success and enhanced patient outcomes.

Commitment to Advancing Patient Care

Beyond technological innovation, Pulmatrix is driven by a commitment to improving patient care on a fundamental level. The targeted delivery approach facilitated by its iSPERSE platform is designed to achieve higher local drug concentrations, which can result in more effective treatment outcomes with reduced systemic side effects. This patient-centric strategy not only addresses unmet therapeutic needs in respiratory and CNS disorders but also underscores the company’s broader mission of leveraging advanced science to improve quality of life. The holistic integration of research, technology, and clinical insight exemplifies Pulmatrix’s dedication to advancing healthcare standards through smart and efficient drug delivery mechanisms.

Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) reported its Q1 2021 financial results, highlighting significant business updates. The company regained full rights to its narrow spectrum kinase inhibitor portfolio, including PUR1800, following the termination of its agreement with Johnson & Johnson. A Phase 1b clinical study on PUR1800 is ongoing, with top-line data expected in Q4 2021. Financially, Pulmatrix reported a revenue of $1.4 million for Q1 2021, down from $2.8 million in 2020. The company ended the quarter with $63.4 million in cash, compared to $31.7 million at the end of 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
-
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) will host a key opinion leader (KOL) webinar on its orally inhaled therapy PUR3100 for acute migraine treatment on April 23, 2021. The event will feature expert discussions on the treatment landscape and the potential of dihydroergotamine (DHE) therapies. CEO Ted Raad will provide insights into the business strategy behind PUR3100, which is currently in preclinical investigation, with Phase 1 and Phase 2 data expected in 2022. Registration for the webinar is available online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.13%
Tags
none
-
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) announced it will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, after Johnson & Johnson's decision to terminate their licensing agreement. Ongoing clinical studies for PUR1800 in treating acute exacerbations of COPD (AECOPD) are progressing, with expected topline data in Q4 2021. A Phase 2 efficacy study is planned for 2022. Notably, toxicology studies indicate favorable outcomes, enhancing the potential for long-term dosing applications. The market potential for PUR1800 could reach approximately $2.5 billion in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.98%
Tags
none
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) has regained full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following the termination of its agreement with Johnson & Johnson. The company plans to advance PUR1800's development with ongoing clinical and toxicology studies for treating acute exacerbations in COPD and other chronic airway diseases. The recent studies show promising results, indicating potential long-term dosing benefits. Pulmatrix anticipates topline data from its Phase 1b clinical study in Q4 2021 and expects a Phase 2b efficacy study to begin later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.28%
Tags
none
-
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) reported its Q4 and full year 2020 financial results, showing a revenue increase to $12.6 million from $7.9 million in 2019. The company completed a registered direct offering, raising $40 million to fund ongoing studies including the PUR1800 Phase 1b. Notable studies include the initiation of the Phase 1b for PUR1800, expected data release in Q4 2021, and efforts for the Pulmazole Phase 2b study. The net loss for 2020 was $19.3 million, largely driven by project costs related to Pulmazole and PUR1800.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
-
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) provides an update on its clinical pipeline and financing. The company has dosed 3 out of 15 patients in a Phase 1b trial for PUR1800, with top-line data expected in Q4 2021. It plans to initiate a Phase 2b study for Pulmazole in Q1 2022, pending committee approval. PUR3100 showed promising results in a dog study, aiming for a Phase 1/2 trial start in Q1 2022. Additionally, Pulmatrix completed a direct offering with $40 million in proceeds, strengthening its financial position for ongoing studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.09%
Tags
none
Rhea-AI Summary

Pulmatrix, a clinical stage biopharmaceutical company, has successfully completed a registered direct offering, selling 20 million shares at a gross amount of $40 million. The offering was facilitated by H.C. Wainwright & Co. The net proceeds are intended for working capital and general corporate purposes. This transaction follows the registration under Form S-3 with the SEC, initially filed in March 2019. Pulmatrix focuses on developing inhaled therapies for serious diseases, including treatments for lung conditions like allergic bronchopulmonary aspergillosis and lung cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
-
Rhea-AI Summary

Pulmatrix (NASDAQ: PULM) has entered into agreements for a registered direct offering of 20 million shares at $2.00 per share, aiming to raise $40 million before expenses. The closing is expected around February 16, 2021, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The funds will support working capital and general corporate purposes. The offering is made under a previously filed shelf registration statement with the SEC, ensuring compliance with regulatory requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.15%
Tags
-
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) reported its Q3 2020 financial results, showcasing a revenue increase to $4.4 million, up from $1.4 million in Q3 2019. The company had $34.5 million in cash as of September 30, 2020. Pulmatrix plans to advance multiple programs, including the anticipated clinical trial of PUR1800 in early 2021, targeting lung cancer. Additionally, the launch of FEND, an OTC nasal hygiene product, provides potential for escalating royalties. However, net loss increased to $10.6 million, attributed to warrant inducement expenses and costs related to clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Pulmatrix, Inc. (NASDAQ: PULM) announced the commercial launch of FEND, a nasal mister product designed to combat COVID-19 by reducing respiratory droplets. Developed in partnership with Sensory Cloud, FEND incorporates Pulmatrix's proprietary NasoCalm formulations. Clinical studies show that FEND can lower exhaled aerosol particles by up to 99% for six hours. With expected escalating royalties from sales, the launch may provide additional revenue to support Pulmatrix's iSPERSE™ technology for inhaled therapies focused on serious lung diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.2%
Tags
none

FAQ

What is the current stock price of Pulmatrix (PULM)?

The current stock price of Pulmatrix (PULM) is $6.06 as of April 2, 2025.

What is the market cap of Pulmatrix (PULM)?

The market cap of Pulmatrix (PULM) is approximately 22.4M.

What is Pulmatrix's primary business focus?

Pulmatrix develops novel inhaled therapeutic products using its proprietary iSPERSE technology to address respiratory and CNS disorders with significant unmet medical needs.

How does the iSPERSE technology work?

The technology produces small, dense, and dispersible particles that enable efficient deep lung delivery, enhancing local therapeutic concentrations while reducing systemic exposure.

What types of drug substances can be delivered using this platform?

The platform is versatile and can accommodate small molecules, peptides, proteins, and nucleic acids, making it relevant for a wide array of therapeutic applications.

How does Pulmatrix differentiate itself from traditional inhalation therapies?

Its advanced particle engineering creates highly efficient drug delivery systems that ensure superior deposition in the lungs compared to conventional aerosolized therapies.

Which therapeutic areas does Pulmatrix target?

The company focuses on respiratory diseases, like COPD and pulmonary infections, as well as central nervous system disorders such as acute migraine.

What role do strategic partnerships play in Pulmatrix's business model?

Partnerships and licensing agreements enhance the commercialization potential of its iSPERSE platform, providing financial flexibility and market access to support its clinical programs.

How does Pulmatrix ensure compliance with industry regulations?

The company rigorously adheres to clinical safety protocols and quality control standards, engaging regularly with regulatory agencies to ensure its trials meet all necessary guidelines.

What sets Pulmatrix apart in the competitive biopharmaceutical landscape?

Its unique focus on engineered dry powder technology and targeted inhalation delivery offers a distinct competitive edge by addressing challenges inherent in traditional drug delivery methods.
Pulmatrix

Nasdaq:PULM

PULM Rankings

PULM Stock Data

22.44M
3.63M
0.65%
9.01%
0.95%
Biotechnology
Pharmaceutical Preparations
Link
United States
FRAMINGHAM